Table 3.
Association between a personal history of autoimmune and other chronic diseases and de novo and therapy-related MDS.
| Controls N = 694 |
De novo MDS N = 356 |
Therapy-related MDS N = 39 |
|||||
|---|---|---|---|---|---|---|---|
| N (%) | N (%) | aOR1 (95% CI) | p-value | N (%) | aOR1 (95% CI) | p-value | |
| Autoimmune diseases | |||||||
| Any autoimmune disease | 272 (19.7) | 103 (28.9) | 1.35 (0.99–1.83) | 0.06 | 14 (35.9) | 1.94 (0.95–3.94) | 0.07 |
| None | 1110 (80.3) | 253 (71.1) | Ref | 25 (64.1) | Ref | ||
| Hypothyroidism | 47 (6.8) | 42 (11.9) | 1.97 (1.25–3.12) | 0.004 | 8 (20.5) | 3.44 (1.42–8.32) | 0.006 |
| None | 647 (93.2) | 312 (88.1) | Ref | 31 (79.5) | Ref | ||
| Rheumatoid arthritis | 60 (8.7) | 29 (8.2) | 0.78 (0.49–1.26) | 0.31 | 3 (7.7) | - | - |
| None | 634 (91.4) | 326 (91.8) | Ref | 36 (92.3) | |||
| Hyperthyroidism | 36 (5.2) | 22 (6.2) | 1.10 (0.62–1.95) | 0.74 | 1 (2.6) | - | - |
| None | 658 (94.8) | 332 (93.8) | Ref | 38 (97.4) | |||
| Inflammatory Bowel Disease | 19 (2.7) | 16 (4.5) | 1.75 (0.87–3.50) | 0.11 | 2 (5.1) | - | - |
| 674 (97.3) | 339 (95.4) | Ref | 37 (94.9) | ||||
| Polymyositis, dermatomyositis, or polymyalgia rheumatica | 8 (1.1) | 11 (3.1) | 2.38 (0.93–6.09) | 0.07 | - | - | - |
| None | 684 (98.8) | 344 (96.9) | Ref | 39 (100.0) | |||
| Other chronic diseases | |||||||
| High blood pressure | 376 (54.1) | 206 (58.0) | 0.99 (0.74–1.31) | 0.91 | 17 (43.6) | 0.82 (0.40–1.68) | 0.59 |
| None | 318 (45.8) | 149 (42.0) | Ref | 22 (56.4) | Ref | ||
| Heart disease, angina or heart attack | 143 (20.6) | 121 (34.1) | 1.74 (1.28–2.37) | 0.0004 | 7 (18.0) | 1.17 (0.48–2.85) | 0.74 |
| None | 550 (79.3) | 234 (65.9) | Ref | 32 (82.1) | Ref | ||
| Osteoarthritis | 141 (20.3) | 71 (20.0) | 0.92 (0.66–1.28) | 0.61 | 8 (20.5) | 1.10 (0.48–2.51) | 0.82 |
| None | 552 (79.7) | 284 (80.0) | Ref | 31 (79.5) | Ref | ||
| Diabetes mellitus (>30 y) | 113 (16.3) | 69 (19.4) | 1.20 (0.84–1.70) | 0.32 | 6 (15.4) | 1.113 (0.44–2.92) | 0.80 |
| None | 581 (83.7) | 286 (80.6) | Ref | 33 (84.6 | Ref | ||
| Eczema | 58 (8.4) | 33 (9.3) | 1.13 (0.72–1.79) | 0.57 | - | - | - |
| None | 633 (91.6) | 323 (90.7) | Ref | 39 (100.0) | |||
| Infectious mononucleosis | 43 (6.2) | 18 (5.1) | 1.01 (0.56–1.80) | 0.98 | 6 (15.4) | 2.23 (0.86–5.77) | 0.10 |
| None | 649 (93.8) | 338 (94.9) | Ref | 33 (84.6) | Ref | ||
| Peptic ulcer | 44 (6.4) | 24 (6.8) | 0.93 (0.55–1.58) | 0.79 | 4 (10.3) | 2.13 (0.70–6.44) | 0.18 |
| None | 649 (93.6) | 331 (93.2) | Ref | 35 (89.7) | Ref | ||
| Contact dermatitis | 24 (3.5) | 18 (5.1) | 1.36 (0.71–2.58) | 0.36 | - | - | - |
| None | 668 (96.5) | 338 (94.9) | Ref | 38 (100.0) | |||
| Cirrhosis of the liver | 12 (1.7) | 8 (2.25) | 1.47 (0.58–3.80) | 0.41 | 1 (2.6) | ||
| None | 680 (98.2) | 348 (97.8) | Ref | 38 (97.4) | |||
| Chronic fatigue syndrome | 6 (0.9) | 12 (3.4) | 4.12 (1.49–11.4) | 0.006 | 1 (2.6) | - | - |
| None | 686 (99.1) | 344 (96.6) | Ref | 38 (97.4) | |||
aOR = adjusted odds ratio; BMI: body mass index; CI = confidence interval; HS: high school; MDS: myelodysplastic syndrome; NSAID: nonsteroidal anti-inflammatory drug.
Numbers in tables may not sum to total number of cases/controls due to missing values.
1
ORs adjusted for age (continuous), sex, education (≤ HS grad, some post HS, college grad), NSAID use, exposure to benzene, BMI 2 years ago (< 25.0, 25.0–29.9, ≥ 30.0)